MD REYAD UL FERDOUS | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. MD REYAD UL FERDOUS | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

postdoctoral at Tsinghua University, China

Md. Reyad-ul-Ferdous is a dedicated researcher specializing in endocrinology, metabolism, and pharmaceutical sciences. With extensive experience in drug discovery and metabolic disease research, he has made significant contributions to the study of mitochondrial function, obesity-related diseases, and liver disorders. His academic and professional journey spans multiple prestigious institutions, including the Chinese Academy of Sciences, Tsinghua University, and Shandong University. Over the years, he has published in peer-reviewed journals, contributed to book chapters, and led innovative research in pharmaceutical technology. His expertise covers a broad spectrum, including natural product chemistry, bioinformatics, CRISPR-Cas9, and metabolic disease modeling. With a strong commitment to scientific advancement, he actively participates in global collaborations, striving to develop novel therapeutic solutions.

Professional Profile

Education

Md. Reyad-ul-Ferdous earned his Ph.D. in Biochemistry and Molecular Biology from the Chinese Academy of Sciences, focusing on drug molecules modulating UCP1 expression in adipocytes. Before that, he completed an M. Pharm in Pharmaceutical Technology and Biopharmaceutics from North South University, Bangladesh, where he researched oral thin film formulations. His B. Pharm in Pharmacy from State University of Bangladesh laid the foundation for his pharmaceutical expertise, with research on phytochemical screenings. Additionally, he pursued online certifications from University of California, San Francisco; University of Maryland; and Vanderbilt University to enhance his knowledge in diabetes, genetics, and personalized medicine. His strong academic background, combined with advanced training in pharmaceutical sciences, has equipped him with a diverse skill set in drug discovery, metabolic research, and clinical applications.

Professional Experience

Currently, Md. Reyad-ul-Ferdous is a Postdoctoral Research Scientist at Tsinghua University’s Institute of Biopharmaceutical and Health Engineering, where he investigates obesity-related disorders and drug formulations. Previously, he worked as a Postdoctoral Researcher at Shandong University, focusing on lipid metabolism, mitochondrial function, and non-alcoholic fatty liver disease (NAFLD/NASH). His early career included serving as a Lecturer in Pharmacy at Shamoli Ideal Medical Institute and Progati Medical Institute in Bangladesh, where he contributed to pharmaceutical education. Throughout his professional journey, he has worked on multiple national and international research projects, collaborating with top-tier institutions to develop therapeutic interventions. His hands-on expertise in drug screening, disease modeling, and pharmacological research has positioned him as a valuable contributor to the global scientific community.

Research Interests

Md. Reyad-ul-Ferdous focuses on metabolic diseases, mitochondrial function, and drug discovery. His primary interest lies in browning white adipose tissue to combat obesity and developing novel therapeutics for NAFLD, NASH, and liver diseases. He is also exploring the gut microbiota’s role in liver diseases, aiming to develop targeted treatments for metabolic disorders. With expertise in pharmaceutical formulations and natural product pharmacology, he investigates bioactive compounds, antioxidants, and flavonoids as potential therapeutic agents. His multidisciplinary approach includes CRISPR-Cas9, cell culture, bioinformatics, and pharmacogenomics, making his research highly relevant to personalized medicine. By integrating biochemistry, molecular biology, and pharmaceutical sciences, he aims to develop innovative treatments for obesity-related diseases, metabolic dysfunctions, and liver fibrosis.

Awards and Honors

Md. Reyad-ul-Ferdous has received multiple prestigious awards and scholarships in recognition of his scientific contributions. He was awarded the CAS-TWAS President Fellowship Program, the Chinese Scholarship Council (CSC) Scholarship, and the Postdoctoral Research Grants from the National Natural Science Foundation of China. He has also been honored as a Lead Guest Editor for scientific journals such as the American Journal of Clinical and Experimental Medicine and the American Journal of BioScience. Additionally, he participated in the 2019 ANSO Young Scientists Forum and Zhejiang International Science and Technology Cooperation Conference, further establishing his global research presence. His numerous grants and research fellowships highlight his dedication to advancing pharmaceutical and metabolic disease research.

Conclusion

Md. Reyad-ul-Ferdous is a highly qualified researcher with strong academic credentials, significant postdoctoral experience, and expertise in metabolic disease research. His contributions to pharmaceutical sciences, obesity-related drug discovery, and mitochondrial function research make him a strong contender for the Best Researcher Award.

Publications Top Noted

  • Title: Present biological status of potential medicinal plant of Amaranthus viridis: a comprehensive review
    Author: M Reyad-ul-Ferdous, DS Shahjahan, S Tanvir, M Mukti
    Year: 2015
    Cited by: 75

  • Title: Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose tissue
    Author: Y Qiu, Y Sun, D Xu, Y Yang, X Liu, Y Wei, Y Chen, Z Feng, S Li, …
    Year: 2018
    Cited by: 44

  • Title: Biologically potential for pharmacologicals and phytochemicals of medicinal plants of Colocasia esculenta: A comprehensive review
    Author: M Reyad-ul-Ferdous, MSI Arman, MMI Tanvir, S Sumi, K Siddique, …
    Year: 2015
    Cited by: 32

  • Title: Significant effect of NSP-ase enzyme supplementation in sunflower meal-based diet on the growth and nutrient digestibility in broilers
    Author: M Bilal, MA Mirza, M Kaleem, M Saeed, M Reyad-ul-Ferdous, …
    Year: 2017
    Cited by: 21

  • Title: Ex-Vivo anti-inflammatory and antimicrobial activities of the leaves of Bauhinia acuminata
    Author: M Reyad-Ul-Ferdous, MZIK Sayma Akhter, ME Khan, MA Islam, MS Ullah
    Year: 2014
    Cited by: 20

  • Title: Ex-vivo cardioprotective and cytotoxic screening of fruits of Parmentiera cereifera seem
    Author: M Reyad-ul-Ferdous, TT Alam, MA Islam, MZI Khan, F Tasnim, ME Khan, …
    Year: 2014
    Cited by: 18

  • Title: Inhibition of insulin degrading enzyme to control diabetes mellitus and its applications on some other chronic disease: A critical review
    Author: MS Azam, M Wahiduzzaman, M Reyad-ul-Ferdous, MN Islam, M Roy
    Year: 2022
    Cited by: 17

  • Title: Investigation of the medicinal potentials of Syzygium jambos (L.) extract and characterization of the isolated compounds
    Author: M Haque, MM Begum, M Hasan, AFMT Rahman, MI Hussain, …
    Year: 2015
    Cited by: 15

  • Title: Berberine chloride (dual topoisomerase I and II inhibitor) modulate mitochondrial uncoupling protein (UCP1) in molecular docking and dynamic with in-vitro cytotoxic and …
    Author: MR Ferdous, M Abdalla, M Yang, L Xiaoling, Y Song
    Year: 2023
    Cited by: 14

  • Title: Liver cyclophilin D deficiency inhibits the progression of early NASH by ameliorating steatosis and inflammation
    Author: X Li, M Yang, H Sun, MR ul Ferdous, L Gao, J Zhao, Y Song
    Year: 2022
    Cited by: 14

  • Title: Baicalein modulates mitochondrial function by upregulating mitochondrial uncoupling protein-1 (UCP1) expression in brown adipocytes, cytotoxicity, and computational studies
    Author: M Reyad-ul-Ferdous, Y Song
    Year: 2022
    Cited by: 12

  • Title: Glycyrrhizin (Glycyrrhizic Acid) HMGB1 (high mobility group box 1) inhibitor upregulate mitochondrial function in adipocyte, cell viability and in-silico study
    Author: M Reyad-ul-Ferdous, M Abdalla, Y Song
    Year: 2022
    Cited by: 12

  • Title: Preliminary in vitro biological and phytochemical screenings of Parmentiera cereifera Seem
    Author: M Reyad-ul-Ferdous, RB Rashid, MAA Sikder, F Aktar, MA Rashid
    Year: 2012
    Cited by: 12

  • Title: Phytochemical screening, in-vitro membrane stabilizing and thrombo-lytic activities of Lophopetalum javanicum
    Author: M Reyad-ul-Ferdous, MG Azam, MD Hossain
    Year: 2014
    Cited by: 10

  • Title: Evaluation of antioxidant, analgesic and antidiarrheal activities of methanolic extract of Litsea monopetala (roxb.) leaves
    Author: MR Ferdous, M Ashrafudolla, MS Hossain, SF Bellah
    Year: 2018
    Cited by: 9

  • Title: Evaluation of Ex-Vivo Anti-inflammatory and total phenolic content of fruits of Parmentiera cereifera seem
    Author: M Reyad-ul-Ferdous, MI Hussain, M Mukti, MA Islam, MN Islam, …
    Year: 2015
    Cited by: 9

  • Title: Screening of Antioxidant and Antimicrobial Properties of the Syzygium jambos L.
    Author: MM Begum, M Haque, M Reyad-ul-Ferdous, M Hasan, H Tarek, …
    Year: 2015
    Cited by: 8

  • Title: Epigenetic drug (XL019) JAK2 inhibitor increases mitochondrial function in brown adipocytes by upregulating mitochondrial uncoupling protein 1 (UCP1), screening of epigenetic …
    Author: M Reyad-ul-Ferdous, M Abdalla, M Yang, L Xiaoling, W Bian, J Xie, …
    Year: 2022
    Cited by: 7

  • Title: Roundness and taper of holes during drilling composites of various thickness by HSS drill bit under dry condition
    Author: MS Sakib, M Rahman, M Ferdous, NR Dhar
    Year: 2017
    Cited by: 7

  • Title: Evaluation of Potential Antioxidant Activity of Leaves of Bauhinia Acuminate: Evaluation of Potential Antioxidant Activity of Leaves
    Author: M Reyad-ul-Ferdous, F Liza, TT Alam, F Tasnim, M Mukti, ME Khan, …
    Year: 2014
    Cited by: 7

 

Ravivats | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Posted on by ScienceFather

Dr. Ravi vats | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Scientist at Q32 bio, United States

Dr. Ravi Vats is a passionate scientist specializing in pharmacology, currently working as a Scientist 1 at Q32 Bio Inc. in Waltham, MA, USA. He holds a wealth of experience in assay validation, technology transfer, and biomarker evaluation in clinical trials. His research career began at the University of Pittsburgh, where he made significant contributions to studies involving sickle cell disease and its complications. Over the years, he has honed his expertise in advanced imaging techniques, including intravital imaging, and artificial intelligence-based digital image analysis. Throughout his career, Dr. Vats has been committed to bridging the gap between experimental research and its clinical applications, with a strong focus on drug development. His collaborative work across various research teams and partnerships with external organizations, including vendors and CROs, has positioned him as a key figure in his field. Dr. Vats is known for his dedication, innovative approaches, and contributions to biomedical research.

Professional Profile

Education

Dr. Ravi Vats earned his PhD in pharmacology from the University of Pittsburgh’s Vascular Medicine Institute (VMI). His doctoral research focused on the pathophysiology of sickle cell disease (SCD), investigating mechanisms like platelet aggregation and vaso-occlusion, with notable work on drug interventions for managing SCD complications. Prior to his PhD, Dr. Vats obtained a Bachelor’s degree in a relevant field, where he laid the foundation for his career in biomedical research. Throughout his academic journey, he worked alongside esteemed scientists, contributing to projects that explored the role of inflammation, blood cell interactions, and vascular health. Dr. Vats has continuously developed his scientific knowledge through his post-doctoral studies and professional roles. His academic background has provided him with a solid theoretical and practical foundation in molecular pharmacology, translational research, and preclinical drug development, making him well-equipped to tackle complex scientific challenges in his field.

Professional Experience

Dr. Vats’ professional journey includes roles at prominent pharmaceutical and research institutions, demonstrating a progressive career in pharmacology and biomedical research. Since November 2022, he has been a Scientist 1 at Q32 Bio, where he supports drug development through preclinical pharmacology studies and leads biomarker evaluations for clinical trials. Previously, he worked at Forma Therapeutics, where he independently designed and executed biomarker studies. His earlier postdoctoral work at the University of Pittsburgh’s Vascular Medicine Institute involved evaluating new drug candidates for sickle cell disease, particularly CSL889, during vaso-occlusive crises. As a graduate student, Dr. Vats published numerous influential research papers, contributing to high-impact journals. He also served as an imaging specialist at the VMI, developing expertise in advanced imaging techniques like multi-photon fluorescence microscopy. Throughout his career, Dr. Vats has collaborated with CROs, vendors, and internal stakeholders, showcasing his leadership and ability to manage complex research projects.

Research Interests

Dr. Ravi Vats’ primary research interests focus on the pharmacology of vascular diseases, with a particular emphasis on sickle cell disease (SCD) and related complications. His work has investigated the mechanisms underlying blood vessel occlusion, platelet aggregation, and inflammation, which are key drivers in diseases like SCD. He is also deeply interested in exploring the role of biomarkers in drug development, particularly in the context of validating new therapeutic targets. Dr. Vats’ expertise extends to the use of advanced imaging techniques, including intravital imaging and digital analysis, to gain deeper insights into disease pathogenesis and to assess therapeutic efficacy. Furthermore, he is actively involved in evaluating novel technologies for use in research and clinical trials. By focusing on both basic and translational research, Dr. Vats aims to contribute to the development of more effective treatments for complex diseases, bridging the gap between preclinical findings and clinical applications.

Awards and Honors

Throughout his distinguished career, Dr. Ravi Vats has earned recognition for his contributions to pharmacology and biomedical research. He has been a key contributor to several collaborative projects that have led to publications in high-impact journals, earning him acknowledgment within the scientific community. His work on sickle cell disease has been highlighted in publications like JCI Insight, where he was a co-author of research on lung vaso-occlusion and micro emboli. Although specific awards and honors are not detailed in the provided profile, his academic journey and professional accomplishments indicate his reputation within the scientific community. Dr. Vats has also received numerous opportunities to work at esteemed institutions and with global leaders in pharmacology, underscoring his expertise and value in advancing clinical research. His involvement in high-level projects and studies suggests that he is a respected figure in the areas of pharmacology, biomarker research, and drug development.

Conclusion

Dr. Ravi Vats is undoubtedly a strong candidate for the Best Researcher Award. His work in biomarker studies, assay validation, and innovative technology application, coupled with his leadership in coordinating research efforts, makes him a standout researcher in his field. By expanding his publication portfolio and increasing his public and translational research efforts, he could further strengthen his profile and make an even larger impact on the scientific and medical community. Based on his current achievements, he has proven himself as an exceptional researcher with the potential to continue making groundbreaking contributions in pharmacology and disease research.

Publications Top Noted

  • Subcutaneous injection of IHP-102 prevents lung vaso-occlusion in sickle cell disease mice
    • Authors: Dubey, R.K., Vats, R., Brzoska, T., Paderi, J., Sundd, P.
    • Journal: Haematologica, 2024, 109(4), pp. 1259–1263
    • Citations: 0
  • Lung microvascular occlusion by platelet-rich neutrophil-platelet aggregates promotes cigarette smoke-induced severe flu
    • Authors: Kaminski, T.W., Brzoska, T., Li, X., Nyunoya, T., Sundd, P.
    • Journal: JCI Insight, 2024, 9(2), e167299
    • Citations: 6
  • Liver-to-lung microembolic NETs promote gasdermin D–dependent inflammatory lung injury in sickle cell disease
    • Authors: Vats, R., Kaminski, T.W., Brzoska, T., Gladwin, M.T., Sundd, P.
    • Journal: Blood, 2022, 140(9), pp. 1020–1037
    • Citations: 43
  • Defenestrated endothelium delays liver-directed gene transfer in hemophilia A mice
    • Authors: Kaminski, T.W., Ju, E.-M., Gudapati, S., Sundd, P., Pradhan-Sundd, T.
    • Journal: Blood Advances, 2022, 6(12), pp. 3729–3734
    • Citations: 4
  • Intravital imaging reveals inflammation as a dominant pathophysiology of age-related hepatovascular changes
    • Authors: Vats, R., Li, Z., Ju, E.-M., Watkins, S., Pradhan-Sundd, T.
    • Journal: American Journal of Physiology – Cell Physiology, 2022, 322(3), pp. C508–C520
    • Citations: 6
  • Single cell RNA sequencing identifies IGFBP5 and QKI as ciliated epithelial cell genes associated with severe COPD
    • Authors: Li, X., Noell, G., Tabib, T., Faner, R., Nyunoya, T.
    • Journal: Respiratory Research, 2021, 22(1), 100
    • Citations: 17
  • Intravital Imaging of Hepatic Blood Biliary Barrier in Live Mice
    • Authors: Vats, R., Kaminski, T.W., Pradhan-Sundd, T.
    • Journal: Current Protocols, 2021, 1(10), e256
    • Citations: 5
  • Compensatory hepatic adaptation accompanies permanent absence of intrahepatic biliary network due to YAP1 loss in liver progenitors
    • Authors: Molina, L.M., Zhu, J., Li, Q., Bell, A., Monga, S.P.
    • Journal: Cell Reports, 2021, 36(1), 109310
    • Citations: 22
  • P-selectin deficiency promotes liver senescence in sickle cell disease mice
    • Authors: Vats, R., Kaminski, T.W., Ju, E.-M., Sundd, P., Pradhan-Sundd, T.
    • Journal: Blood, 2021, 137(19), pp. 2676–2680
    • Citations: 11
  • Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease
    • Authors: Vats, R., Liu, S., Zhu, J., Monga, S.P., Pradhan-Sundd, T.
    • Journal: Hepatology, 2020, 72(6), pp. 2165–2181
    • Citations: 15